Rett In The News
February 1, 2021
Taysha Gene Therapies, Inc. has highlighted its strategic priorities and provided a business outlook for 2021.
Neurogene and University of Edinburgh Announce Research Collaboration to Advance Next Generation Gene Therapies
January 19, 2021
Neurogene Inc. has announced a collaboration to advance development of multiple platform approaches designed to enable next generation gene therapies.
January 14, 2021
Two unpublished studies detail improved methods for delivering gene therapies to the brain: One involves a type of stem cell that can produce gene-altering proteins on-site; the other taps an engineered virus to target neurons efficiently and noninvasively.
The New York Times
December 19, 2020
Clusters of living brain cells are teaching scientists about diseases like autism. With a new finding, some experts wonder if these organoids may become too much like the real thing.
October 14, 2020
A gene therapy for Angelman syndrome stands at the forefront of efforts to treat autism-linked conditions that stem from single genes.
October 3, 2020
October is Rett Syndrome Month. It's a rare and very challenging disease that affects just one in 10,000 girls. It's a tough go, but there is hope. Tim Freeman from the Rett Syndrome Research Trust tells us more.
August 27, 2020
Problems with the formation of DNA-filled droplets that control gene expression may contribute to Rett syndrome, a new study suggests.
Taysha Gene Therapies
Taysha Gene Therapies Announces Oversubscribed $95 Million Series B Financing to Bolster Initial Clinical Studies in GM2 Gangliosidosis and Advance Pipeline of Gene Therapies for Monogenic CNS Disease in Both Rare and Large Patient Populations
August 5, 2020
Taysha Gene Therapies, a patient-centric gene therapy company with a mission to eradicate monogenic CNS disease, today announced that it has closed an oversubscribed $95 million Series B financing with a premier syndicate of life science investors, led by Fidelity Management & Research ...
Biotech Vico Therapeutics raises $31 million (€27 million) in Series A financing round to advance therapies for rare central nervous system diseases
July 29, 2020
Vico Therapeutics, a Leiden, the Netherlands, based biotech company focusing on the development of RNA modulating therapies for rare neurological disorders, today announced that it has raised $31 million (€27 million) in a Series A financing round.
Scientific first: RNA repair shows promise in reversing mutations underlying a neurological disorder
July 14, 2020
OHSU study first to use programmable RNA editing to repair gene that contributes to Rett syndrome.
The New York Times
July 7, 2020
Our executive director, Monica Coenraads, and her daughter are featured on the front page of the NYT science section.
June 11, 2020
The coronavirus pandemic has stretched hospital resources beyond their capacity, disrupted the delivery of care, and drained providers of billions of dollars of revenue for canceled elective procedures, office visits, and tests.
April 29, 2020
The world's largest brain research prize is Danish and is awarded by the Lundbeck Foundation. Each year, we award 10 million DKK (approx. 1,3 million€) to one or more brain researchers who have had a ground-breaking impact on brain research.
The New York Times
April 17, 2020
There’s more than meets the eye — here are some tips to help avoid confusion.
March 1, 2020
When X-linked genes evade silencing on the “inactive” chromosome in XX cells, some protect women from diseases such as cancer, but others seem to promote conditions such as autoimmunity.
February 11, 2020
Gene or genome editing describes a process by which targeted and deliberate changes to the DNA sequence are made. Recent advances in programmable nucleases, including the CRISPR-Cas9 system, mean that manipulating DNA has never been easier, which could fundamentally alter the way we treat and ...